InVitae Corp Company Profile (NASDAQ:NVTA)

About InVitae Corp (NASDAQ:NVTA)

InVitae Corp logoInvitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company's products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Diagnostics & Testing
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NVTA
  • CUSIP: N/A
  • Web: https://www.invitae.com
Capitalization:
  • Market Cap: $397.33 million
  • Outstanding Shares: 42,314,000
Average Prices:
  • 50 Day Moving Avg: $9.41
  • 200 Day Moving Avg: $9.72
  • 52 Week Range: $5.76 - $11.88
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.76
  • P/E Growth: -0.49
Sales & Book Value:
  • Annual Revenue: $31.43 million
  • Price / Sales: 12.64
  • Book Value: $1.95 per share
  • Price / Book: 4.82
Profitability:
  • EBIDTA: ($95,640,000.00)
  • Net Margins: -260.48%
  • Return on Equity: -119.10%
  • Return on Assets: -76.26%
Misc:
  • Average Volume: 281,210 shs.
  • Short Ratio: 9.37
 
Frequently Asked Questions for InVitae Corp (NASDAQ:NVTA)

What is InVitae Corp's stock symbol?

InVitae Corp trades on the NASDAQ under the ticker symbol "NVTA."

How were InVitae Corp's earnings last quarter?

InVitae Corp (NASDAQ:NVTA) posted its earnings results on Tuesday, May, 9th. The company reported ($0.64) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.68) by $0.04. The firm earned $10.34 million during the quarter, compared to analysts' expectations of $10.90 million. InVitae Corp had a negative net margin of 260.48% and a negative return on equity of 119.10%. The company's quarterly revenue was up 161.1% compared to the same quarter last year. During the same period last year, the company posted ($0.80) EPS. View InVitae Corp's Earnings History.

Where is InVitae Corp's stock going? Where will InVitae Corp's stock price be in 2017?

3 equities research analysts have issued 1-year price objectives for InVitae Corp's shares. Their forecasts range from $12.00 to $16.00. On average, they anticipate InVitae Corp's stock price to reach $14.00 in the next twelve months. View Analyst Ratings for InVitae Corp.

Who are some of InVitae Corp's key competitors?

Who are InVitae Corp's key executives?

InVitae Corp's management team includes the folowing people:

  • Randal W. Scott Ph.D., Executive Chairman of the Board
  • Sean E. George Ph.D., President, Chief Executive Officer, Co-Founder, Director
  • Shelly D. Guyer, Chief Financial Officer
  • Lee Bendekgey J.D., Chief Operating Officer, General Counsel, Secretary
  • Robert L. Nussbaum M.D., Chief Medical Officer
  • Christine M. Gorjanc, Lead Independent Director
  • Eric Aguiar M.D., Independent Director
  • Geoffrey S. Crouse, Independent Director

When did InVitae Corp IPO?

(NVTA) raised $76 million in an initial public offering (IPO) on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

How do I buy InVitae Corp stock?

Shares of InVitae Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is InVitae Corp's stock price today?

One share of InVitae Corp stock can currently be purchased for approximately $9.39.


MarketBeat Community Rating for InVitae Corp (NASDAQ NVTA)
Community Ranking:  1.8 out of 5 ()
Outperform Votes:  54 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  147
MarketBeat's community ratings are surveys of what our community members think about InVitae Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for InVitae Corp (NASDAQ:NVTA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.00 (49.09% upside)

Analysts' Ratings History for InVitae Corp (NASDAQ:NVTA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/3/2017Benchmark Co.Reiterated RatingBuy -> Buy$11.00 -> $16.00HighView Rating Details
11/9/2016Leerink SwannReiterated RatingOutperformN/AView Rating Details
8/9/2016J P Morgan Chase & CoBoost Price TargetOverweight$12.00 -> $14.00N/AView Rating Details
8/14/2015William BlairInitiated CoverageMarket PerformN/AView Rating Details
(Data available from 7/25/2015 forward)

Earnings

Earnings History for InVitae Corp (NASDAQ:NVTA)
Earnings by Quarter for InVitae Corp (NASDAQ:NVTA)
Earnings History by Quarter for InVitae Corp (NASDAQ NVTA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.68)($0.64)$10.90 million$10.34 millionViewListenView Earnings Details
2/13/2017Q416($0.73)($0.69)$8.82 million$9.20 millionViewN/AView Earnings Details
11/7/2016Q316($0.72)($0.77)$7.50 million$6.30 millionViewListenView Earnings Details
8/8/2016Q216($0.76)($0.77)$5.81 million$5.60 millionViewN/AView Earnings Details
5/9/2016Q116($0.76)($0.80)$4.38 million$4.00 millionViewN/AView Earnings Details
2/9/2016Q415($0.72)($0.76)$2.92 million$3.20 millionViewN/AView Earnings Details
11/5/2015Q315($0.70)($0.71)$2.55 million$2.19 millionViewN/AView Earnings Details
8/6/2015Q215($0.55)($0.76)$1.67 million$1.80 millionViewN/AView Earnings Details
5/12/2015Q115($0.51)($1.09)$1.07 million$1.23 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for InVitae Corp (NASDAQ:NVTA)
2017 EPS Consensus Estimate: ($2.45)
2018 EPS Consensus Estimate: ($1.48)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.68)($0.65)($0.67)
Q2 20172($0.64)($0.58)($0.61)
Q3 20172($0.62)($0.58)($0.60)
Q4 20172($0.57)($0.57)($0.57)
Q1 20181($0.43)($0.43)($0.43)
Q2 20181($0.43)($0.43)($0.43)
Q3 20181($0.40)($0.40)($0.40)
Q4 20181($0.22)($0.22)($0.22)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for InVitae Corp (NASDAQ:NVTA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for InVitae Corp (NASDAQ:NVTA)
Insider Trades by Quarter for InVitae Corp (NASDAQ:NVTA)
Institutional Ownership by Quarter for InVitae Corp (NASDAQ:NVTA)
Insider Trades by Quarter for InVitae Corp (NASDAQ:NVTA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/16/2017Thomas BridaGeneral CounselSell766$9.69$7,422.54View SEC Filing  
2/15/2017E Lee BendekgeyCFOSell2,098$9.59$20,119.82View SEC Filing  
2/15/2017Patty DumondVPSell1,264$9.55$12,071.20View SEC Filing  
2/15/2017Robert L NussbaumInsiderSell1,686$9.53$16,067.58View SEC Filing  
2/15/2017Thomas BridaGeneral CounselSell794$9.54$7,574.76View SEC Filing  
11/22/2016Randal W ScottChairmanBuy66,666$6.00$399,996.00View SEC Filing  
11/18/2016Geoffrey CrouseDirectorBuy15,000$6.25$93,750.00View SEC Filing  
11/17/2016Bros. Advisors Lp BakerMajor ShareholderBuy733,333$6.00$4,399,998.00View SEC Filing  
9/16/2016Patty DumondVPSell1,000$8.00$8,000.00View SEC Filing  
8/15/2016Patty DumondVPSell1,000$8.81$8,810.00View SEC Filing  
7/14/2016Patty DumondVPSell1,000$8.79$8,790.00View SEC Filing  
6/16/2016Patty DumondVPSell1,000$8.00$8,000.00View SEC Filing  
5/17/2016Patty DumondVPSell3,221$8.47$27,281.87View SEC Filing  
4/14/2016Patty DumondVPSell1,000$10.50$10,500.00View SEC Filing  
2/22/2016Lisa AldersonInsiderSell7,500$7.64$57,300.00View SEC Filing  
2/11/2016Sean E GeorgeCOOBuy16,950$6.16$104,412.00View SEC Filing  
2/18/2015James E FlynnInsiderBuy175,000$16.00$2,800,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for InVitae Corp (NASDAQ:NVTA)
Latest Headlines for InVitae Corp (NASDAQ:NVTA)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to Invitae Corp. : July 24, 2017
finance.yahoo.com - July 25 at 6:17 AM
finance.yahoo.com logoInvitae to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 7, 2017
finance.yahoo.com - July 24 at 8:59 AM
americanbankingnews.com logoAnalyzing InVitae Corp (NASDAQ:NVTA) & Veracyte (VCYT)
www.americanbankingnews.com - July 20 at 12:40 PM
finance.yahoo.com logoETFs with exposure to Invitae Corp. : July 14, 2017
finance.yahoo.com - July 15 at 7:03 AM
americanbankingnews.com logoInVitae Corp (NASDAQ:NVTA) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - July 14 at 5:04 PM
finance.yahoo.com logoInvitae Corp. breached its 50 day moving average in a Bullish Manner : NVTA-US : July 12, 2017
finance.yahoo.com - July 13 at 7:31 AM
americanbankingnews.com logoInVitae Corp (NVTA) vs. DIGILITI MONEY (DGLT) Head-To-Head Analysis
www.americanbankingnews.com - July 11 at 12:22 PM
americanbankingnews.com logo Analysts Expect InVitae Corp (NASDAQ:NVTA) Will Announce Quarterly Sales of $13.02 Million
www.americanbankingnews.com - July 8 at 8:38 AM
americanbankingnews.com logo Brokerages Expect InVitae Corp (NASDAQ:NVTA) to Post -$0.61 EPS
www.americanbankingnews.com - July 6 at 4:24 PM
finance.yahoo.com logoETFs with exposure to Invitae Corp. : June 29, 2017
finance.yahoo.com - June 30 at 2:43 AM
finance.yahoo.com logoInvitae Corp. breached its 50 day moving average in a Bearish Manner : NVTA-US : June 28, 2017
finance.yahoo.com - June 28 at 1:46 PM
americanbankingnews.com logoInVitae Corp (NVTA) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - June 19 at 4:40 PM
americanbankingnews.com logoZacks: Brokerages Expect InVitae Corp (NVTA) Will Announce Quarterly Sales of $13.02 Million
www.americanbankingnews.com - June 14 at 11:12 AM
finance.yahoo.com logoFeatured Company News - Invitae Acquires Ommdom; Gets CancerGene Connect Under its Portfolio
finance.yahoo.com - June 14 at 9:09 AM
americanbankingnews.com logoInVitae Corp (NVTA) Expected to Announce Earnings of -$0.61 Per Share
www.americanbankingnews.com - June 12 at 4:46 PM
streetinsider.com logoInVitae (NVTA) Acquires CancerGene Connect
www.streetinsider.com - June 12 at 4:18 PM
finance.yahoo.com logoInvitae Acquires CancerGene Connect, Award-Winning Risk Assessment and Family History Analysis Platform
finance.yahoo.com - June 12 at 8:47 AM
finance.yahoo.com logoETFs with exposure to Invitae Corp. : June 5, 2017
finance.yahoo.com - June 5 at 7:34 PM
finance.yahoo.com logoASCO Data Shows Prostate Cancer Patients with Genetic Risk Factors Missed Under Current Testing Guidelines
finance.yahoo.com - June 5 at 8:43 AM
americanbankingnews.com logoValuEngine Upgrades InVitae Corp (NVTA) to Sell
www.americanbankingnews.com - June 3 at 10:04 PM
finance.yahoo.com logoInvitae Corp. :NVTA-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 8:47 PM
americanbankingnews.com logoQ2 2017 EPS Estimates for InVitae Corp (NVTA) Decreased by Analyst
www.americanbankingnews.com - June 2 at 7:08 AM
finance.yahoo.com logoInvitae to present at the Goldman Sachs 38th Annual Global Healthcare Conference
finance.yahoo.com - June 1 at 7:48 PM
seekingalpha.com logoHow The Media Has Failed - The Invitae Story Is Strong
seekingalpha.com - May 31 at 11:27 AM
finance.yahoo.com logoHow the Media Has Failed -- The Invitae (NVTA) Story is Strong - Yahoo News
finance.yahoo.com - May 27 at 7:18 PM
baystreet.ca logoHow the Media Has Failed – The Invitae (NVTA) Story is Strong
www.baystreet.ca - May 26 at 5:19 AM
finance.yahoo.com logoInvitae Broadens Management Team to Scale Expanding Business and Meet Rising Demand
finance.yahoo.com - May 26 at 5:19 AM
americanbankingnews.com logoInVitae Corp (NVTA) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 23 at 4:38 PM
americanbankingnews.com logoInVitae Corp (NVTA) Lowered to "Strong Sell" at ValuEngine
www.americanbankingnews.com - May 23 at 3:08 PM
americanbankingnews.com logoInVitae Corp (NVTA) Expected to Post Quarterly Sales of $12.87 Million
www.americanbankingnews.com - May 21 at 6:36 PM
americanbankingnews.com logoAnalysts Anticipate InVitae Corp (NVTA) to Post ($0.61) EPS
www.americanbankingnews.com - May 17 at 12:44 AM
americanbankingnews.com logo-$0.61 EPS Expected for InVitae Corp (NVTA) This Quarter
www.americanbankingnews.com - May 16 at 9:22 AM
finance.yahoo.com logoInvitae to Present at the UBS Global Healthcare Conference
finance.yahoo.com - May 12 at 8:33 AM
americanbankingnews.com logoQ2 2017 EPS Estimates for InVitae Corp (NVTA) Lifted by Analyst
www.americanbankingnews.com - May 11 at 8:08 AM
finance.yahoo.com logoInvitae Corp. breached its 50 day moving average in a Bearish Manner : NVTA-US : May 10, 2017
finance.yahoo.com - May 10 at 11:56 AM
americanbankingnews.com logoInVitae Corp (NVTA) Announces Earnings Results
www.americanbankingnews.com - May 9 at 3:44 PM
finance.yahoo.com logoInvitae Exceeds 26,000 Samples Accessioned, Reports Revenue of $10.3 Million and Net Loss of $0.64 Per Share in First Quarter 2017
finance.yahoo.com - May 8 at 6:23 PM
americanbankingnews.com logoBrokerages Anticipate InVitae Corp (NVTA) to Post ($0.68) Earnings Per Share
www.americanbankingnews.com - May 1 at 10:30 AM
americanbankingnews.com logoInVitae Corp (NVTA) Getting Somewhat Favorable Media Coverage, Analysis Finds
www.americanbankingnews.com - April 29 at 7:58 PM
finance.yahoo.com logoETFs with exposure to Invitae Corp. : April 28, 2017
finance.yahoo.com - April 28 at 7:55 PM
finance.yahoo.com logoNew research suggests current genetic testing guidelines may miss breast cancer patients who could benefit from testing
finance.yahoo.com - April 28 at 8:45 AM
americanbankingnews.com logoZacks: Brokerages Expect InVitae Corp (NVTA) Will Post Quarterly Sales of $10.88 Million
www.americanbankingnews.com - April 27 at 12:20 PM
finance.yahoo.com logoInvitae to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
finance.yahoo.com - April 27 at 10:08 AM
americanbankingnews.com logoZacks: Brokerages Anticipate InVitae Corp (NVTA) to Post -$0.68 EPS
www.americanbankingnews.com - April 25 at 2:15 PM
finance.yahoo.com logoInvitae Corp. – Value Analysis (NYSE:NVTA) : April 24, 2017
finance.yahoo.com - April 24 at 5:51 PM
finance.yahoo.com logoInvitae to Announce First Quarter 2017 Financial Results and Host Conference Call on May 8, 2017
finance.yahoo.com - April 24 at 12:29 PM
finance.yahoo.com logoInvitae Corp. breached its 50 day moving average in a Bullish Manner : NVTA-US : April 21, 2017
finance.yahoo.com - April 21 at 9:24 AM
finance.yahoo.com logoInvitae announces expansion of its genetic test menu with addition of new tests and expanded panels for …
finance.yahoo.com - April 20 at 9:20 AM
finance.yahoo.com logoInvitae announces expansion of its genetic test menu with addition of new tests and expanded panels for inherited metabolic and immune system disorders, including panels to confirm diagnoses suggested by newborn screening
finance.yahoo.com - April 20 at 9:20 AM
americanbankingnews.com logoInVitae Corp (NVTA) Getting Positive Media Coverage, Analysis Finds
www.americanbankingnews.com - April 14 at 3:46 PM

Social

Chart

InVitae Corp (NVTA) Chart for Tuesday, July, 25, 2017

This page was last updated on 7/25/2017 by MarketBeat.com Staff